<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:36:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10134315" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10134315</identifier>
        <datestamp>2023-04-28</datestamp>
        <setSpec>canmed</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cam45619" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
              <journal-id journal-id-type="publisher-id">CAM4</journal-id>
              <journal-title-group>
                <journal-title>Cancer Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-7634</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10134315</article-id>
              <article-id pub-id-type="pmcid">PMC10134315</article-id>
              <article-id pub-id-type="pmc-uid">10134315</article-id>
              <article-id pub-id-type="pmid">36645168</article-id>
              <article-id pub-id-type="pmid">36645168</article-id>
              <article-id pub-id-type="doi">10.1002/cam4.5619</article-id>
              <article-id pub-id-type="publisher-id">CAM45619</article-id>
              <article-id pub-id-type="other">CAM4-2022-07-3004.R2</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>RESEARCH ARTICLES</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Clinical Cancer Research</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects</article-title>
                <alt-title alt-title-type="left-running-head">Nakamura et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cam45619-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Nakamura</surname>
                    <given-names>Zev M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9695-1457</contrib-id>
                  <xref rid="cam45619-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>zev_nakamura@med.unc.edu</email>
                  </address>
                </contrib>
                <contrib id="cam45619-cr-0002" contrib-type="author">
                  <name>
                    <surname>Deal</surname>
                    <given-names>Allison M.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0003" contrib-type="author">
                  <name>
                    <surname>Park</surname>
                    <given-names>Eliza M.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0004" contrib-type="author">
                  <name>
                    <surname>Stanton</surname>
                    <given-names>Kate E.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0005" contrib-type="author">
                  <name>
                    <surname>Lopez</surname>
                    <given-names>Yesy E.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0006" contrib-type="author">
                  <name>
                    <surname>Quillen</surname>
                    <given-names>Laura J.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0007" contrib-type="author">
                  <name>
                    <surname>O’Hare Kelly</surname>
                    <given-names>Erin</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0008" contrib-type="author">
                  <name>
                    <surname>Heiling</surname>
                    <given-names>Hillary M.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0009" contrib-type="author">
                  <name>
                    <surname>Nyrop</surname>
                    <given-names>Kirsten A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2974-480X</contrib-id>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0010" contrib-type="author">
                  <name>
                    <surname>Ray</surname>
                    <given-names>Emily M.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0011" contrib-type="author">
                  <name>
                    <surname>Dees</surname>
                    <given-names>E. Claire</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0012" contrib-type="author">
                  <name>
                    <surname>Reeder‐Hayes</surname>
                    <given-names>Katherine E.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6903-0177</contrib-id>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0013" contrib-type="author">
                  <name>
                    <surname>Jolly</surname>
                    <given-names>Trevor A.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0014" contrib-type="author">
                  <name>
                    <surname>Carey</surname>
                    <given-names>Lisa A.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0015" contrib-type="author">
                  <name>
                    <surname>Abdou</surname>
                    <given-names>Yara</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4827-8613</contrib-id>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0016" contrib-type="author">
                  <name>
                    <surname>Olajide</surname>
                    <given-names>Oludamilola A.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0017" contrib-type="author">
                  <name>
                    <surname>Rauch</surname>
                    <given-names>Julia K.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0018" contrib-type="author">
                  <name>
                    <surname>Joseph</surname>
                    <given-names>Ranjit</given-names>
                  </name>
                  <xref rid="cam45619-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0019" contrib-type="author">
                  <name>
                    <surname>Copeland</surname>
                    <given-names>Anureet</given-names>
                  </name>
                  <xref rid="cam45619-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0020" contrib-type="author">
                  <name>
                    <surname>McNamara</surname>
                    <given-names>Megan A.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0021" contrib-type="author">
                  <name>
                    <surname>Ahles</surname>
                    <given-names>Tim A.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cam45619-cr-0022" contrib-type="author">
                  <name>
                    <surname>Muss</surname>
                    <given-names>Hyman B.</given-names>
                  </name>
                  <xref rid="cam45619-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cam45619-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="cam45619-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychiatry</named-content>
                <institution>University of North Carolina at Chapel Hill</institution>
                <city>Chapel Hill</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45619-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Lineberger Comprehensive Cancer Center</named-content>
                <institution>University of North Carolina at Chapel Hill</institution>
                <city>Chapel Hill</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45619-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Oncology, Department of Medicine</named-content>
                <institution>University of North Carolina at Chapel Hill</institution>
                <city>Chapel Hill</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45619-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Rex Hematology Oncology Associates</named-content>
                <institution>Rex Cancer Care</institution>
                <city>Raleigh</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam45619-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychiatry and Behavioral Sciences</named-content>
                <institution>Memorial Sloan Kettering Cancer Center</institution>
                <city>New York</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Zev M. Nakamura, Department of Psychiatry, University of North Carolina, 101 Manning Drive, Campus Box #7160, Chapel Hill, North Carolina 27599, USA.<break/>
Email: <email>zev_nakamura@med.unc.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="500">7</issue>
              <issue-id pub-id-type="doi">10.1002/cam4.v12.7</issue-id>
              <fpage>8172</fpage>
              <lpage>8183</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>29</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>13</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>31</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CAM4-12-8172.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="cam45619-sec-0001">
                  <title>Background</title>
                  <p>Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in these patients. This trial examined the feasibility, tolerability, acceptability, and preliminary effects of memantine to prevent cognitive decline during chemotherapy for breast cancer.</p>
                </sec>
                <sec id="cam45619-sec-0002">
                  <title>Methods</title>
                  <p>Patients with stage I–III breast cancer, scheduled for neo/adjuvant chemotherapy, completed a cognitive battery prior to and 4 weeks after completing chemotherapy. Memantine (10 mg BID) was administered concurrent with chemotherapy. Our primary cognitive outcome was visual working memory assessed by the Delayed Matching to Sample test. We used the Brief Medication Questionnaire to assess acceptability.</p>
                </sec>
                <sec id="cam45619-sec-0003">
                  <title>Results</title>
                  <p>Of 126 patients approached, 56 (44%) enrolled. Forty‐five (80%) received ≥1 dose of memantine and completed pre‐post assessments. Seventy‐six percent reported taking ≥90% of scheduled doses. Participants were mean age of 56, 77% White, and 57% had stage I disease. Sixty‐four percent had stable or improved Delayed Matching to Sample test scores. Stable or improved cognition was observed in 87%–91% across objective cognitive domain composite measures. Sixty‐six percent self‐reported stable or improved cognitive symptoms. There were seven greater than or equal to grade 3 adverse events; two were possibly related to memantine. Only 5% reported that taking memantine was a disruption to their lives.</p>
                </sec>
                <sec id="cam45619-sec-0004">
                  <title>Conclusions</title>
                  <p>Memantine was well‐tolerated and consistently taken by a large majority of patients receiving breast cancer chemotherapy. The majority demonstrated stable or improved cognition from pre‐ to post‐assessment. Randomized trials are needed to determine memantine's efficacy to ameliorate cognitive loss.</p>
                </sec>
                <sec id="cam45619-sec-0005">
                  <title>Trial Registration</title>
                  <p><ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> NCT04033419.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <p>Memantine is a feasible, safe, and acceptable intervention to mitigate cognitive decline in patients who receive chemotherapy for early‐stage breast cancer. The majority demonstrated stable or improved cognition from pre‐ to post‐assessment. Randomized trials are needed to determine memantine's efficacy to ameliorate cognitive loss.<boxed-text position="anchor" content-type="graphic" id="cam45619-blkfxd-0001"><graphic xlink:href="CAM4-12-8172-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cam45619-kwd-0001">behavioral science</kwd>
                <kwd id="cam45619-kwd-0002">breast cancer</kwd>
                <kwd id="cam45619-kwd-0003">cancer‐related cognitive impairment</kwd>
                <kwd id="cam45619-kwd-0004">clinical trials</kwd>
                <kwd id="cam45619-kwd-0005">cognitive dysfunction</kwd>
                <kwd id="cam45619-kwd-0006">memantine</kwd>
                <kwd id="cam45619-kwd-0007">quality of life</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Breast Cancer Research Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/100001006</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development
</institution>
                      <institution-id institution-id-type="doi">10.13039/100009633</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5K12HD001441</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>Kay Yow Foundation</funding-source>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>5K07CA218167</award-id>
                  <award-id>5P30CA016086</award-id>
                  <award-id>5P50CA058223</award-id>
                  <award-id>5R01CA218496</award-id>
                  <award-id>P30CA008748</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>University Cancer Research Fund</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="4"/>
                <page-count count="12"/>
                <word-count count="6723"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:27.04.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CAM45619-cit-2001"><string-name><surname>Nakamura</surname><given-names>ZM</given-names></string-name>, <string-name><surname>Deal</surname><given-names>AM</given-names></string-name>, <string-name><surname>Park</surname><given-names>EM</given-names></string-name>, et al. <article-title>A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>:<fpage>8172</fpage>‐<lpage>8183</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.5619</pub-id>
</mixed-citation>
              </p>
              <fn-group id="cam45619-ntgp-0001">
                <fn id="cam45619-note-0001">
                  <p>Tim A. Ahles and Hyman B. Muss co‐senior authorship.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="cam45619-body-0001">
            <sec id="cam45619-sec-0006">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Cancer‐related cognitive impairment (CRCI) is a common and consequential condition described in many cancers and following a myriad of cancer‐directed therapies.<xref rid="cam45619-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="cam45619-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="cam45619-bib-0003" ref-type="bibr"><sup>3</sup></xref> One suspected cause of CRCI is chemotherapy, with as many as 75% of patients with breast cancer self‐reporting cognitive decline during chemotherapy.<xref rid="cam45619-bib-0001" ref-type="bibr"><sup>1</sup></xref> CRCI can present major barriers to returning to pre‐cancer occupational and social role function and has been described as one of the most concerning issues for cancer survivors.<xref rid="cam45619-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam45619-bib-0005" ref-type="bibr"><sup>5</sup></xref>
</p>
              <p>Pharmacotherapies for CRCI present potential advantages over behavioral interventions, including targeting precise mechanisms, minimizing patient time investment, and requiring few facility resources. However, there have been &lt;10 randomized controlled trials (RCTs) of medications for CRCI and the only agents that have been studied for CRCI prevention during chemotherapy–Ginkgo biloba, erythropoietin, and methylphenidate–have not been effective and/or presented acceptability and safety concerns.<xref rid="cam45619-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam45619-bib-0007" ref-type="bibr"><sup>7</sup></xref> This gap is critical because: (1) CRCI is common; (2) associated with substantial morbidity; and (3) may represent irreversible changes to brain structure and function.<xref rid="cam45619-bib-0008" ref-type="bibr"><sup>8</sup></xref>
</p>
              <p>Memantine, an <italic toggle="yes">N</italic>‐methyl‐<sc>d</sc>‐aspartate receptor antagonist, is a compelling medication to investigate for CRCI prevention during chemotherapy. Multi‐center studies in patients with brain metastases undergoing whole brain radiotherapy have demonstrated that memantine mitigates decline in executive function, memory, and processing speed and is now included in guideline recommendations.<xref rid="cam45619-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cam45619-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="cam45619-bib-0011" ref-type="bibr"><sup>11</sup></xref> More recently, pre‐clinical studies suggest that memantine may prevent cognitive effects of chemotherapy through modulation of neuroinflammation and brain‐derived neurotrophic factor, ultimately preserving hippocampal neurogenesis.<xref rid="cam45619-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cam45619-bib-0013" ref-type="bibr"><sup>13</sup></xref> Nonetheless, memantine's potential promise for CRCI has yet to be studied in clinical populations during chemotherapy. In this single‐arm trial, we assessed the feasibility, tolerability, and acceptability of memantine administration concurrent with neo/adjuvant chemotherapy for breast cancer. We examined pre‐post changes in objective and patient‐reported cognition.</p>
            </sec>
            <sec sec-type="methods" id="cam45619-sec-0007">
              <label>2</label>
              <title>METHODS</title>
              <sec id="cam45619-sec-0008">
                <label>2.1</label>
                <title>Design and study sample</title>
                <p>In this phase II, single‐arm trial, we recruited 56 patients scheduled to begin neo/adjuvant chemotherapy for stage I–III breast cancer at the University of North Carolina (UNC) Health System's North Carolina Cancer Center, Hillsborough Hospital, and Rex Cancer Center between September 2019 and August 2021. Participants completed a cognitive assessment prior to initiating chemotherapy (pre‐) and 4 weeks after (post‐) their final cycle. Memantine was administered twice daily (BID) between pre‐ and post‐assessments. The study was approved by the UNC Institutional Review Board and UNC Lineberger Protocol Review Committee. The trial is registered at <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> number NCT04033419.</p>
              </sec>
              <sec id="cam45619-sec-0009">
                <label>2.2</label>
                <title>Eligibility criteria</title>
                <p>Participants were: (1) diagnosed with stage I–III breast cancer; (2) scheduled for neo/adjuvant chemotherapy; (3) ≥18 years of age; (4) able to speak English; and (5) able to provide informed consent. Exclusion criteria were: (1) history of an adverse reaction to memantine; (2) another cancer diagnosis with estimated survival &lt;5 years; (3) previous chemotherapy; (4) severe cognitive impairment, defined as Blessed Orientation‐Memory‐Concentration Test<xref rid="cam45619-bib-0014" ref-type="bibr"><sup>14</sup></xref> score ≥11; (5) pregnant or breast feeding; or (6) current alcohol or drug abuse.</p>
              </sec>
              <sec id="cam45619-sec-0010">
                <label>2.3</label>
                <title>Intervention</title>
                <p>Participants started memantine no earlier than 4 weeks prior and no later than 1 week after their first cycle of chemotherapy. The dose was titrated as follows: 5 mg daily in week 1, 5 mg BID in week 2, 5 mg each morning, and 10 mg each evening in week 3, then 10 mg BID in week 4. Participants continued 10 mg BID (or highest tolerated dose) until 4 weeks after (range: 2–12 weeks) their final cycle of chemotherapy.</p>
              </sec>
              <sec id="cam45619-sec-0011">
                <label>2.4</label>
                <title>Acceptability</title>
                <p>The Brief Medication Questionnaire (BMQ)‐Specific contains 10, 5‐point Likert scale items (1 = strongly disagree to 5 = strongly agree) that assess patients' beliefs about the necessity of and concerns about taking a medication for their illness.<xref rid="cam45619-bib-0015" ref-type="bibr"><sup>15</sup></xref> We modified items to reflect statements specific to memantine and cognition.</p>
              </sec>
              <sec id="cam45619-sec-0012">
                <label>2.5</label>
                <title>Adverse events (<styled-content style="fixed-case" toggle="no">AE</styled-content>)</title>
                <p>Participants were evaluated for toxicity with the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE v 5) weekly during the 4‐week titration and every 2–3 weeks thereafter, coinciding with chemotherapy infusion. Though all patient‐reported symptoms were recorded, we explicitly solicited the most common side effects of memantine (headache, dizziness, confusion, constipation, diarrhea, and fatigue). Attribution was defined as <italic toggle="yes">unrelated</italic>, <italic toggle="yes">unlikely</italic>, <italic toggle="yes">possible</italic>, <italic toggle="yes">probable</italic>, or <italic toggle="yes">definite</italic> based on a priori criteria (Table <xref rid="cam45619-supitem-0001" ref-type="supplementary-material">S1</xref>). To provide additional indirect safety information, independent of AE attribution, we monitored the rate and reasons for chemotherapy dose reduction.</p>
              </sec>
              <sec id="cam45619-sec-0013">
                <label>2.6</label>
                <title>Measures</title>
                <sec id="cam45619-sec-0014">
                  <label>2.6.1</label>
                  <title>Neuropsychological assessment</title>
                  <p>The Cambridge Neuropsychological Test Automated Battery (CANTAB) is comprised of highly sensitive and well‐validated computer‐based tests of cognition.<xref rid="cam45619-bib-0016" ref-type="bibr"><sup>16</sup></xref> Three CANTAB measures–Delayed Matching to Sample (DMS), Rapid Visual Processing, and One Touch Stockings of Cambridge–were chosen for this study based on their previous use in the CRCI field.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam45619-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam45619-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="cam45619-bib-0020" ref-type="bibr"><sup>20</sup></xref> We chose the DMS % correctly at 12 s delay, a measure of visual working memory, as our primary outcome as it was recently shown to be especially sensitive to CRCI.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref> During the DMS, participants are briefly shown a sample image with a complex visual pattern. Then, after a delay (up to 12 s long), they are asked to identify from a set of four similar appearing patterns the image that exactly matches the original sample.</p>
                  <p>Additionally, we administered paper‐based, traditional neuropsychological measures with well‐established track records in oncology (Table <xref rid="cam45619-supitem-0001" ref-type="supplementary-material">S2</xref>). To facilitate interpretability of our objective cognitive outcomes, we also constructed composite measures of attention, working memory, and executive function (AWE), learning and memory (LM), and global cognition, as has been described in prior CRCI studies (Table <xref rid="cam45619-supitem-0001" ref-type="supplementary-material">S2</xref>).<xref rid="cam45619-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cam45619-bib-0022" ref-type="bibr"><sup>22</sup></xref> Though the original protocol was designed for in‐person assessment, at the start of the COVID‐19 pandemic, the protocol was modified to give participants the choice of whether to complete the cognitive assessment in‐person or remotely.</p>
                </sec>
                <sec id="cam45619-sec-0015">
                  <label>2.6.2</label>
                  <title><styled-content style="fixed-case" toggle="no">Patient‐reported</styled-content> outcome measures</title>
                  <p>We used PROMIS measures to evaluate patient‐reported cognition (Short Form v2.0—Cognitive Function 8a), depression, anxiety, and sleep disturbance.<xref rid="cam45619-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cam45619-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam45619-bib-0025" ref-type="bibr"><sup>25</sup></xref> Scores are reported as a <italic toggle="yes">T</italic>‐score with a mean of 50 and standard deviation (SD) of 10. Higher scores represent better cognitive function, but more severe depression, anxiety, and sleep disturbance. We utilized established thresholds to define normal cognitive function (&gt;45) and mild (&gt;35–45), moderate (&gt;30–35), and severe (≤30) cognitive difficulties.<xref rid="cam45619-bib-0025" ref-type="bibr"><sup>25</sup></xref> For other PROMIS measures, we examined the proportion with at least moderately severe symptoms.<xref rid="cam45619-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam45619-bib-0025" ref-type="bibr"><sup>25</sup></xref>
</p>
                </sec>
                <sec id="cam45619-sec-0016">
                  <label>2.6.3</label>
                  <title>Disease characteristics</title>
                  <p>Tumor stage, HER2 and hormone receptor (HR) positivity, history of surgery and radiation, and chemotherapy regimen were abstracted from the medical record.</p>
                </sec>
              </sec>
              <sec id="cam45619-sec-0017">
                <label>2.7</label>
                <title>Statistical analysis</title>
                <sec id="cam45619-sec-0018">
                  <label>2.7.1</label>
                  <title>Power and sample size</title>
                  <p>For the primary cognitive outcome (change in DMS % correct at 12 s delay), we determined that a sample size of 45 participants was needed. A paired <italic toggle="yes">t</italic>‐test with 0.05 one‐sided significance level has 80% power to detect an effect size of 0.38 (3% mean increase in the DMS score with SD of 8%) compared to the null hypothesized change from a historical control of patients with early‐stage breast cancer receiving chemotherapy who did not receive any intervention for cognition.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref> To account for dropout of up to 20%, we enrolled 56 participants.</p>
                </sec>
                <sec id="cam45619-sec-0019">
                  <label>2.7.2</label>
                  <title>Data analysis</title>
                  <p>Descriptive statistics were used to characterize participants and evaluate aspects of feasibility (recruitment, retention, adherence), tolerability, and acceptability. A paired <italic toggle="yes">t</italic>‐test was used to test if the change in DMS score between pre‐post assessments was statistically different from historical controls. To evaluate other changes in objective cognition, we evaluated meaningful pre‐ to post‐assessment improvement or decline (defined as ≥0.5 SD) in all composite domains and individual measures. For patient‐reported cognition, we used established thresholds to define clinically meaningful changes (e.g., normal function to mild difficulties, mild difficulties to moderate difficulties, etc.).<xref rid="cam45619-bib-0025" ref-type="bibr"><sup>25</sup></xref> A priori we stipulated that all participants who received at least one dose of memantine would be evaluated for toxicity and that all participants who received at least one dose of memantine and completed the DMS at pre‐ and post‐timepoints would be evaluated for cognitive changes. We compared participant characteristics between the 45 subjects who completed the primary cognitive outcome and the 11 who did not using Fisher's exact tests for categorical and Wilcoxon rank sum tests for continuous characteristics.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="cam45619-sec-0020">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="cam45619-sec-0021">
                <label>3.1</label>
                <title>Participant characteristics</title>
                <p>On average, enrolled participants were 56 years old (range: 27–78; Table <xref rid="cam45619-tbl-0001" ref-type="table">1</xref>). Seventy‐seven percent were White, 18% were Black, and 5% were other races. Fifty‐seven percent had stage I disease, 68% had HR+ tumors, and 29% HER2+ tumors. Sixty‐four percent had prior lumpectomy or mastectomy. At least moderately severe psychological comorbidities were present in 6% (anxiety), 2% (depression), and 26% (sleep disturbance) at baseline and 11% (anxiety), 2% (depression), and 20% (sleep disturbance) at post‐assessment. Participants who initiated memantine and completed both pre‐ and post‐assessments had higher levels of education compared to those who did not (16.1 vs. 14.1 years, <italic toggle="yes">p</italic> = 0.03); otherwise, there were no significant differences between groups.</p>
                <table-wrap position="float" id="cam45619-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Participant characteristics (<italic toggle="no">N</italic> = 56)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (%)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, mean (SD), [range], years</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">56.2 (12.8), [27–78]</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Female</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">55 (98.2)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" valign="top" rowspan="1">Race</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">43 (76.8)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (17.9)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (5.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" valign="top" rowspan="1">Ethnicity</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not Hispanic/Latino</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">54 (96.4)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic/Latino</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (3.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Education (years), mean (SD)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.8 (2.2)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Post‐menopausal</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">28 (59.6)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" valign="top" rowspan="1">Stage</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">I</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">32 (57.1)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (26.8)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (16.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HER2+</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16 (28.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HR+</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">38 (67.9)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" valign="top" rowspan="1">Chemotherapy timing</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adjuvant</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">36 (64.3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neoadjuvant</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20 (35.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" valign="top" rowspan="1">Chemotherapy regimen</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Anthracycline‐based</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24 (42.9)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not anthracycline‐based</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">32 (57.1)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Prior radiation</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (3.6)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Anxiety (PROMIS anxiety ≥65)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (5.9)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Depression (PROMIS depression ≥65)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2.0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sleep disturbance (PROMIS sleep disturbance ≥55)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13 (26.0)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45619-ntgp-0002">
                    <fn id="cam45619-note-0002">
                      <p>Abbreviations: HR, hormone receptor; PROMIS, patient‐reported outcomes measurement information system.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam45619-sec-0022">
                <label>3.2</label>
                <title>Feasibility</title>
                <p>Of the 412 patients screened, 126 were eligible and approached, and 56 enrolled (recruitment rate: 44%; Figure <xref rid="cam45619-fig-0001" ref-type="fig">1</xref>). Reasons patients provided for declining participation included not wanting to start an additional medication (<italic toggle="yes">n</italic> = 35), stress about their cancer treatment (<italic toggle="yes">n</italic> = 4), time commitment concerns (<italic toggle="yes">n</italic> = 2), logistical barriers to completing required research activities (<italic toggle="yes">n</italic> = 2), and opposition to participating in research in general (<italic toggle="yes">n</italic> = 1). Fifty‐one participants initiated memantine. Forty‐five had at least one dose of memantine and completed both pre‐ and post‐assessments and, thus, were evaluable for cognitive change (retention rate: 80%). Thirty participants completed both assessments remotely, 11 completed one remotely and one in‐person, and four completed both in‐person.</p>
                <fig position="float" fig-type="FIGURE" id="cam45619-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Modified CONSORT flow diagram for a single‐arm trial of memantine to prevent cognitive decline during chemotherapy for early‐stage breast cancer.</p>
                  </caption>
                  <graphic xlink:href="CAM4-12-8172-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>On average, participants were scheduled for 22 weeks of memantine (SD 9.3). Thirty‐nine participants (76%) reported ≥90% adherence with scheduled doses, two participants (4%) reported 50%–89% adherence, and 10 participants (20%) reported &lt;50% adherence. Independent of overall adherence, 12 participants (24%) discontinued memantine prior to the end of the study. Reasons for discontinuation included side effect concerns by the participant, provider, or study team regardless of formal attribution to memantine (<italic toggle="yes">n</italic> = 9), no specified reason (<italic toggle="yes">n</italic> = 2), and unrelated medical complications (<italic toggle="yes">n</italic> = 1). Six additional participants held memantine temporarily for a median duration of 3.4 weeks (range: 0.9–5.7).</p>
              </sec>
              <sec id="cam45619-sec-0023">
                <label>3.3</label>
                <title>Tolerability</title>
                <p>AEs were generally low grade and not attributed to memantine (Table <xref rid="cam45619-tbl-0002" ref-type="table">2</xref>). Of the seven grade 3 AEs, only two (diarrhea and hypokalemia) had at least <italic toggle="yes">possible</italic> attribution to memantine. The most common AEs (regardless of attribution or severity) were fatigue, headache, constipation, diarrhea, and dizziness, which occurred in 20 (39%), 19 (37%), 14 (27%), 14 (27%), and 12 (24%) participants, respectively. Twenty‐nine participants (57%) had chemotherapy dose reduction. The most common reasons for dose reduction were peripheral neuropathy (<italic toggle="yes">n</italic> = 17), fatigue (<italic toggle="yes">n</italic> = 7), cytopenias (<italic toggle="yes">n</italic> = 4), elevated liver enzymes (<italic toggle="yes">n</italic> = 2), and diarrhea (<italic toggle="yes">n</italic> = 2).</p>
                <table-wrap position="float" id="cam45619-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Adverse events</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Attribution</th>
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">NCI CTCAE grade</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">1</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">2</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">3</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">4</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Unrelated</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">52</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Unlikely</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">54</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Possible</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">37</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Probable</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Definite</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">–</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </sec>
              <sec id="cam45619-sec-0024">
                <label>3.4</label>
                <title>Acceptability</title>
                <p>At the post‐assessment, 16.3% agreed or strongly agreed, 72.1% were unsure, and 11.6% disagreed or strongly disagreed that memantine had protected their cognition from becoming worse (Table <xref rid="cam45619-tbl-0003" ref-type="table">3</xref>). By comparison, 4.6% reported that memantine was a disruption to their lives and 7.0% expressed worries about having to take memantine.</p>
                <table-wrap position="float" id="cam45619-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Responses to BMQ of memantine for cognition (<italic toggle="no">N</italic> = 43)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Item</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Agree or strongly agree (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Uncertain (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Disagree or strongly disagree (%)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">My cognition, at present, depends on memantine</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">46.5</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">46.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Having to take memantine worried me</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">86.0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">My life would have been impossible without memantine</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">32.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">65.1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Without memantine I would have had problems with my cognition</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">55.8</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">I sometimes worried about long‐term effects of memantine</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">72.1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Memantine is a mystery to me</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">48.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">My future cognition will depend on memantine</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">30.2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">67.4</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Memantine disrupted my life</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4.7</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">90.7</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">I sometimes worried about becoming too dependent on memantine</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">83.7</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Memantine protected my cognition from becoming worse</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">72.1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11.6</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </sec>
              <sec id="cam45619-sec-0025">
                <label>3.5</label>
                <title>Objective cognitive changes</title>
                <p>Table <xref rid="cam45619-tbl-0004" ref-type="table">4</xref> indicates the proportion of participants who improved, had no change, or declined across cognitive domains/measures. Most participants had no meaningful change. In the AWE domain, 22.2% improved, 64.4% had no change, and 13.3% declined. In the LM domain, 46.7% improved, 40.0% had no change, and 13.3% declined. In every measure except for the Animal naming test, more participants improved than declined. The DMS raw score improved by 3% (95% CI: −5% to +10%; range: −20% to +40%), which was not significantly different than the 5% raw score improvement in the historical control group of breast cancer patients who received chemotherapy without any intervention for CRCI<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref> (<italic toggle="yes">p</italic> = 0.55). Raw score changes across all cognitive measures are shown in Table <xref rid="cam45619-supitem-0001" ref-type="supplementary-material">S3</xref>. To explore impact of testing administration format, we compared baseline scores in those participants who completed the assessment in‐person (<italic toggle="yes">n</italic> = 20) versus those who completed the assessment remotely (<italic toggle="yes">n</italic> = 33). No meaningful differences were observed (Table <xref rid="cam45619-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                <table-wrap position="float" id="cam45619-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Cognitive changes from pre‐ to post‐assessment (<italic toggle="no">N</italic> = 45)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Measure</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Improved (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No change (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Declined (%)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">AWE<xref rid="cam45619-note-0005" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22.2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">64.4</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Digit span forward</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">68.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Digit span backward</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">28.9</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Controlled oral word association test</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">40.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">40.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20.0</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Animal naming</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22.2</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42.2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Delayed Matching to Sample</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">28.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Rapid visual processing<xref rid="cam45619-note-0006" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">32.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">54.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12.9</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">One Touch Stockings of Cambridge<xref rid="cam45619-note-0006" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">29.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">51.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19.4</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">LM<xref rid="cam45619-note-0007" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">46.7</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">40.0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HVLT‐R total recall</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">48.9</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HVLT‐R delayed recall</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">51.1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">35.6</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Global<xref rid="cam45619-note-0008" ref-type="table-fn"><sup>d</sup></xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">24.4</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">66.7</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8.9</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam45619-ntgp-0003">
                    <fn id="cam45619-note-0003">
                      <p><italic toggle="yes">Note</italic>: Declined and improved defined by ≥0.5 SD change from pre‐ to post‐assessment; no change refers to &lt;0.5 SD change from pre‐ to post‐assessment.</p>
                    </fn>
                    <fn id="cam45619-note-0004">
                      <p>Abbreviations: AWE, attention, working memory, executive function; HVLT‐R, Hopkins Verbal Learning Test‐Revised; LM, learning and memory.</p>
                    </fn>
                    <fn id="cam45619-note-0005">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>AWE: Composite of digit span forward and backward, Controlled Oral Word Association Test, Animal naming, Delayed Matching to Sample, Rapid Visual Processing, and One Touch Stockings of Cambridge.</p>
                    </fn>
                    <fn id="cam45619-note-0006">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Introduced at start of COVID‐19 pandemic. Completed in subset of <italic toggle="yes">n</italic> = 31.</p>
                    </fn>
                    <fn id="cam45619-note-0007">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>LM: Composite of HVLT‐R total and delayed recall.</p>
                    </fn>
                    <fn id="cam45619-note-0008">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Global: Composite of all individual measures in the AWE and LM domains.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam45619-sec-0026">
                <label>3.6</label>
                <title>Patient‐reported cognitive changes</title>
                <p>Overall, 66% (<italic toggle="yes">n</italic> = 29) demonstrated stability or improvement in patient‐reported cognition (Figure <xref rid="cam45619-fig-0002" ref-type="fig">2</xref>). Of the 33 participants with normal cognition at baseline, 18 remained within normal limits, 14 reported decline to mild cognitive difficulties, and one endorsed moderate post‐chemotherapy cognitive problems. Of those with mild difficulties at baseline, two improved to normal function and all others continued to report mild issues.</p>
                <fig position="float" fig-type="FIGURE" id="cam45619-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Changes in severity of self‐reported cognitive difficulties from pre‐ to post‐assessment (<italic toggle="yes">N</italic> = 44).</p>
                  </caption>
                  <graphic xlink:href="CAM4-12-8172-g003" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cam45619-sec-0027">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>We have demonstrated the feasibility, tolerability, and acceptability of memantine in patients with early‐stage breast cancer undergoing chemotherapy. While we did not demonstrate efficacy in this single‐arm trial, a high proportion of participants demonstrated stable or improved cognition, supporting future study of memantine in an adequately powered, controlled trial.</p>
              <p>There are limited data regarding the feasibility of pharmacological interventions for CRCI. However, in a trial of the stimulant methylphenidate administered during chemotherapy for breast cancer, researchers failed to reach target accrual.<xref rid="cam45619-bib-0026" ref-type="bibr"><sup>26</sup></xref> They reported challenges in participants' willingness to take another medication and about methylphenidate specifically. Two other studies involving methylphenidate for CRCI in the brain tumor population also closed prematurely due to slow accrual and/or high dropout.<xref rid="cam45619-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cam45619-bib-0028" ref-type="bibr"><sup>28</sup></xref> By comparison, participants in our study reported few concerns about memantine and optimism about its potential to be helpful to them. Perhaps reflective of participants' concerns about CRCI and acceptability of memantine, rates of recruitment, retention, and adherence were all supportive of the feasibility of this intervention.</p>
              <p>We are among the first to address a major research gap in interventions to prevent cognitive decline during chemotherapy. Specifically, most CRCI interventions have been tested years after completion of primary therapy. While there are many potential reasons for the lack of prevention studies, feasibility is likely among them. For example, a pilot study of the acetylcholinesterase inhibitor donepezil tested during radiation and chemotherapy in brain tumor patients closed prematurely.<xref rid="cam45619-bib-0029" ref-type="bibr"><sup>29</sup></xref> Yet, a pilot RCT of donepezil in breast cancer survivors who had completed adjuvant chemotherapy 1–5 years prior achieved target accrual over a 6‐month recruitment period, retained 76% of patients, and with minimal interruptions to treatment over the 24‐week protocol.<xref rid="cam45619-bib-0030" ref-type="bibr"><sup>30</sup></xref>
</p>
              <p>The safety and tolerability of medications for CRCI, especially when administered during active treatment, is a critical issue. For example, approximately 15 years ago, several small studies of erythropoietin demonstrated mixed effects for CRCI,<xref rid="cam45619-bib-0006" ref-type="bibr"><sup>6</sup></xref> but there have been no additional studies after the FDA issued a warning about it increasing thromboembolic risk in cancer patients.<xref rid="cam45619-bib-0031" ref-type="bibr"><sup>31</sup></xref> Memantine has a strong track record of safety in Alzheimer's disease and other neurodegenerative disorders.<xref rid="cam45619-bib-0032" ref-type="bibr"><sup>32</sup></xref> More recently, a multi‐center study of its use during cranial radiation in patients with brain metastases to prevent cognitive decline showed that its toxicity profile was similar to placebo.<xref rid="cam45619-bib-0010" ref-type="bibr"><sup>10</sup></xref> While attribution of AEs of memantine is complicated by the fact that its most common side effects overlap with those secondary to chemotherapy, the prevalence of several of the most common AEs observed in our study, including fatigue, constipation, and diarrhea, were similar to that described in clinical practice.<xref rid="cam45619-bib-0033" ref-type="bibr"><sup>33</sup></xref>
</p>
              <p>In this early phase study with focus on feasibility, we have contextualized the observed cognitive changes in our cohort to those in observational studies reporting cognitive change during breast cancer chemotherapy. There are several major challenges in comparing data to prior studies, including that most have been small studies, with heterogeneity in measures used to quantify CRCI, and variable approaches to account for the fact that scores on repeated cognitive testing are inflated by enhanced familiarity with the test (i.e., practice effects). Given these issues, we compared the change in our primary outcome (DMS % correct at 12 s delay) to that in the observational study by Janelsins and colleagues–the largest in breast cancer (<italic toggle="yes">N</italic> = 943) examining cognitive function at multiple timepoints relative to chemotherapy.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref> There may be several potential reasons why we failed to demonstrate improvement over the historical control. First, the variance in the DMS in our sample was much larger than we had anticipated (and larger than that of any other measure in our study). Second, though several prior studies suggest that memantine targets working memory (the domain evaluated with the DMS) and related cognitive processes,<xref rid="cam45619-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cam45619-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="cam45619-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="cam45619-bib-0037" ref-type="bibr"><sup>37</sup></xref> it is possible that another measure would have better captured the effects of memantine. Finally, it is also possible that memantine was not beneficial to patients in our study, but it is worth noting that our cohort improved on average on the digit span backward and Controlled Oral Word Association Test (two core CRCI measures) whereas studies by Janelsins et al. and others reported decline in these measures.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam45619-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="cam45619-bib-0039" ref-type="bibr"><sup>39</sup></xref>
</p>
              <p>It is also important to acknowledge that many patients with breast cancer do not experience cognitive decline during chemotherapy. In this study, we focused on the proportion of who experienced clinically meaningful changes in cognition. While prevalence estimates of the proportion of patients who decline in objectively measured cognition varies between ~15% and 50%,<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam45619-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cam45619-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="cam45619-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="cam45619-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="cam45619-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="cam45619-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="cam45619-bib-0043" ref-type="bibr"><sup>43</sup></xref> the fact that we observed decline in ≤13% of participants across composite cognitive domains is encouraging. Further, on individual measures, most patients demonstrated no change from pre‐ to post‐assessment, and in eight of nine objective measures more patients demonstrated clinically meaningful improvement (beyond what would be expected from practice effects alone) than decline.</p>
              <p>In our study, we objectively evaluated cognitive change using a traditional, neuropsychological battery of measures recommended by the International Cognition and Cancer Task Force<xref rid="cam45619-bib-0044" ref-type="bibr"><sup>44</sup></xref> as well as three computerized cognitive tests from the CANTAB battery. The decision to incorporate CANTAB was in response to a call for cognitive neuroscience measures in CRCI research to enhance sensitivity and disentangle deficits in specific cognitive processes not feasible with conventional neuropsychological testing. Additionally, results from the previously described observational study by Janelsins et al. support the sensitivity of the specific CANTAB measures used in our study.<xref rid="cam45619-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam45619-bib-0045" ref-type="bibr"><sup>45</sup></xref> In our planned RCT and other future work, we intend to expand the use of computerized cognitive neuroscience measures and extend beyond traditional accuracy or speed outcomes. For example, evaluating intraindividual variability in performance within and between tasks appears to be a more sensitive approach to identify subtle cognitive changes experienced during chemotherapy.<xref rid="cam45619-bib-0045" ref-type="bibr"><sup>45</sup></xref>, <xref rid="cam45619-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="cam45619-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="cam45619-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="cam45619-bib-0049" ref-type="bibr"><sup>49</sup></xref> In the future RCT, we also plan to facilitate interpretation of observed cognitive changes using reliable change indices<xref rid="cam45619-bib-0050" ref-type="bibr"><sup>50</sup></xref>, <xref rid="cam45619-bib-0051" ref-type="bibr"><sup>51</sup></xref> and enhance sensitivity to detect an effect using “gatekeeper” approaches,<xref rid="cam45619-bib-0052" ref-type="bibr"><sup>52</sup></xref>, <xref rid="cam45619-bib-0053" ref-type="bibr"><sup>53</sup></xref>, <xref rid="cam45619-bib-0054" ref-type="bibr"><sup>54</sup></xref> a method of condensing results from multiple cognitive tests into composite cognitive domain outcomes that has been demonstrated to increase reliability and precision of treatment estimates, improve power, and minimize Type I error, and, thus, is being increasingly utilized in CRCI and other populations.<xref rid="cam45619-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="cam45619-bib-0055" ref-type="bibr"><sup>55</sup></xref>, <xref rid="cam45619-bib-0056" ref-type="bibr"><sup>56</sup></xref>, <xref rid="cam45619-bib-0057" ref-type="bibr"><sup>57</sup></xref>, <xref rid="cam45619-bib-0058" ref-type="bibr"><sup>58</sup></xref>
</p>
              <p>We also found promising early data as it relates to patient‐reported cognitive function. In Janelsins's cohort study, 45% of patients reported clinically significant decline.<xref rid="cam45619-bib-0059" ref-type="bibr"><sup>59</sup></xref> By comparison, in our study, 34% of participants reported clinically significant decline. While the patient‐report measure used in our study (PROMIS Short Form v2.0—Cognitive Function 8a) was not identical to what was used by Janelsins et al. (FACT‐Cog), the PROMIS Cognitive Function measure is almost entirely comprised of items from the FACT‐Cog. Additionally, the low levels of anxiety and depression in our sample and minimal change in these symptoms from pre‐ to post‐assessment suggest that the cognitive changes observed in our cohort were not simply reflective of changes in mental health.</p>
              <sec id="cam45619-sec-0028">
                <label>4.1</label>
                <title>Strengths and limitations</title>
                <p>Strengths of our study include recruitment from multiple sites, high rate of data completion, and inclusion of both objective and patient‐reported cognitive outcomes. There are also notable limitations to acknowledge. Most significantly, the use of a historical control limited our ability to make direct comparisons to evaluate efficacy, and a follow‐up randomized trial is planned for this purpose. Regarding generalizability, participants who enrolled in our study may have had more concerns about their cognition entering treatment and/or were more optimistic about memantine's potential to benefit them, which may have led to bias, especially in patient‐reported symptoms. Participants also had high levels of education and were about 5 years younger than the average age of patients diagnosed with breast cancer.<xref rid="cam45619-bib-0060" ref-type="bibr"><sup>60</sup></xref> Thus, our sample may have had greater cognitive reserve and more resilience to the cognitive impact of their cancer and its treatment. Otherwise, patient and treatment characteristics were largely reflective of clinical populations in the United States Finally, conducting this study during the COVID‐19 pandemic required mid‐study protocol modifications (e.g., mixed in‐person and remote cognitive assessments). However, there is research supporting the equivalency of in‐person and remote cognitive testing and the use of teleneuropsychology during the pandemic has been accepted as a reliable and valid alternative to in‐person assessment.<xref rid="cam45619-bib-0061" ref-type="bibr"><sup>61</sup></xref>, <xref rid="cam45619-bib-0062" ref-type="bibr"><sup>62</sup></xref>, <xref rid="cam45619-bib-0063" ref-type="bibr"><sup>63</sup></xref>, <xref rid="cam45619-bib-0064" ref-type="bibr"><sup>64</sup></xref> To our knowledge, there have not yet been published studies examining the reliability and validity of teleneuropsychology in breast cancer, but its feasibility and acceptability have been demonstrated in other cancer populations.<xref rid="cam45619-bib-0065" ref-type="bibr"><sup>65</sup></xref>
</p>
              </sec>
              <sec id="cam45619-sec-0029">
                <label>4.2</label>
                <title>Conclusions and future directions</title>
                <p>This is one of the first studies to demonstrate that a medication for prevention of cognitive decline during chemotherapy is feasible. As indicated above, we plan to extend this work to next conduct a RCT of memantine in this patient population and treatment setting. Because CRCI is a heterogeneous phenomenon with some patients experiencing substantial decline and others being unaffected, future research aimed at recognizing who is most at risk for cognitive decline during chemotherapy and who may experience most benefit from specific interventions is needed.</p>
              </sec>
            </sec>
            <sec id="cam45619-sec-0035">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Zev M. Nakamura:</bold> Conceptualization (lead); data curation (lead); formal analysis (supporting); funding acquisition (lead); investigation (lead); methodology (lead); project administration (lead); supervision (lead); validation (lead); visualization (lead); writing – original draft (lead); writing – review and editing (lead). <bold>Allison M. Deal:</bold> Conceptualization (supporting); data curation (supporting); formal analysis (lead); methodology (supporting); visualization (supporting); writing – review and editing (supporting). <bold>Eliza M. Park:</bold> Conceptualization (supporting); methodology (supporting); project administration (supporting); supervision (supporting); writing – original draft (supporting); writing – review and editing (supporting). <bold>Kate E. Stanton:</bold> Data curation (supporting); investigation (supporting); resources (supporting); software (supporting); writing – review and editing (supporting). <bold>Yesy E. Lopez:</bold> Data curation (supporting); investigation (supporting); resources (supporting); software (supporting); writing – review and editing (supporting). <bold>Laura J. Quillen:</bold> Data curation (supporting); investigation (supporting); resources (supporting); software (supporting); writing – review and editing (supporting). <bold>Erin O'Hare Kelly:</bold> Investigation (supporting); resources (supporting); writing – review and editing (supporting). <bold>Hillary M. Heiling:</bold> Data curation (supporting); formal analysis (supporting); visualization (supporting); writing – review and editing (supporting). <bold>Kirsten A. Nyrop:</bold> Project administration (supporting); supervision (supporting); writing – review and editing (supporting). <bold>Emily M. Ray:</bold> Resources (supporting); writing – review and editing (supporting). <bold>E. Claire Dees:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Katherine E. Reeder‐Hayes:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Trevor A. Jolly:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Lisa A. Carey:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Yara Abdou:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Oludamilola A. Olajide:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Julia K. Rauch:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Ranjit Joseph:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Anureet Copeland:</bold> Resources (supporting); writing – review and editing (supporting). <bold>Megan A. McNamara:</bold> Project administration (supporting); resources (supporting); writing – review and editing (supporting). <bold>Tim A. Ahles:</bold> Conceptualization (supporting); methodology (supporting); project administration (supporting); supervision (supporting); writing – original draft (supporting); writing – review and editing (supporting). <bold>Hyman B. Muss:</bold> Conceptualization (supporting); funding acquisition (supporting); methodology (supporting); project administration (lead); supervision (supporting); writing – original draft (supporting); writing – review and editing (supporting).</p>
            </sec>
            <sec id="cam45619-sec-0031">
              <title>FUNDING INFORMATION</title>
              <p>This study was supported by the National Institutes of Health (NIH; Grant # 5K12HD001441, Scholar: ZMN; P30CA008748, TAA; 5R01CA218496, TAA; 5K07CA218167, EMP; 5P50CA058223; 5P30CA016086), Breast Cancer Research Foundation (New York, NY; HBM), Kay Yow Foundation (Raleigh, NC; HBM), and the University Cancer Research Fund. The content is solely the responsibility of the authors and does not represent the official views of the NIH.</p>
            </sec>
            <sec sec-type="COI-statement" id="cam45619-sec-0032">
              <title>CONFLICT OF INTEREST</title>
              <p>Emily Ray receives research funding from OptumHealth and Pfizer. E. Claire Dees consults for Sanofi and receives research funding from Novartis, Genentech/Roche, Pfizer, Merck, H3 Biomedicine, and Meryx Pharmaceuticals. Katherine Reeder‐Hayes receives research funding from Pfizer. Lisa Carey receives research funding from Syndax, Novartis, NanoString Technologies, Abbvie, Seattle Genetics, and Veracyte. Yara Abdou consults for Exact Sciences.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cam45619-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Tables S1‐S4
</p>
                </caption>
                <media xlink:href="CAM4-12-8172-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="cam45619-sec-0030">
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank Nancy Burns, Janice Worden, A. Kaitlyn Moore, Sarah Freeman, Kathleen Seymour, Patricia Gothard, and the entire Rex Cancer Care research staff for their contributions to this study.</p>
            </ack>
            <sec sec-type="data-availability" id="cam45619-sec-0034">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>
            </sec>
            <ref-list content-type="cited-references" id="cam45619-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cam45619-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0001"><string-name><surname>Janelsins</surname><given-names>MC</given-names></string-name>, <string-name><surname>Kesler</surname><given-names>SR</given-names></string-name>, <string-name><surname>Ahles</surname><given-names>TA</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>GR</given-names></string-name>. <article-title>Prevalence, mechanisms, and management of cancer‐related cognitive impairment</article-title>. <source>Int Rev Psychiatry</source>. <year>2014</year>;<volume>26</volume>(<issue>1</issue>):<fpage>102</fpage>‐<lpage>113</lpage>.<pub-id pub-id-type="pmid">24716504</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0002"><string-name><surname>Wefel</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kesler</surname><given-names>SR</given-names></string-name>, <string-name><surname>Noll</surname><given-names>KR</given-names></string-name>, <string-name><surname>Schagen</surname><given-names>SB</given-names></string-name>. <article-title>Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults</article-title>. <source>CA Cancer J Clin</source>. <year>2015</year>;<volume>65</volume>(<issue>2</issue>):<fpage>123</fpage>‐<lpage>138</lpage>.<pub-id pub-id-type="pmid">25483452</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0003"><string-name><surname>Van Dyk</surname><given-names>K</given-names></string-name>, <string-name><surname>Ganz</surname><given-names>PA</given-names></string-name>. <article-title>Cancer‐related cognitive impairment in patients with a history of breast cancer</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>17</issue>):<fpage>1736</fpage>‐<lpage>1737</lpage>.<pub-id pub-id-type="pmid">34652424</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0004"><string-name><surname>Ahles</surname><given-names>TA</given-names></string-name>, <string-name><surname>Root</surname><given-names>JC</given-names></string-name>. <article-title>Cognitive effects of cancer and cancer treatments</article-title>. <source>Annu Rev Clin Psychol</source>. <year>2018</year>;<volume>14</volume>:<fpage>425</fpage>‐<lpage>451</lpage>.<pub-id pub-id-type="pmid">29345974</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0005"><string-name><surname>Klaver</surname><given-names>KM</given-names></string-name>, <string-name><surname>Duijts</surname><given-names>SFA</given-names></string-name>, <string-name><surname>Engelhardt</surname><given-names>EG</given-names></string-name>, et al. <article-title>Cancer‐related cognitive problems at work: experiences of survivors and professionals</article-title>. <source>J Cancer Surviv</source>. <year>2020</year>;<volume>14</volume>:<fpage>168</fpage>‐<lpage>178</lpage>.<pub-id pub-id-type="pmid">31768861</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0006"><string-name><surname>Karschnia</surname><given-names>P</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>MW</given-names></string-name>, <string-name><surname>Dietrich</surname><given-names>J</given-names></string-name>. <article-title>Pharmacologic management of cognitive impairment induced by cancer therapy</article-title>. <source>Lancet Oncol</source>. <year>2019</year>;<volume>20</volume>:<fpage>e92</fpage>‐<lpage>e102</lpage>.<pub-id pub-id-type="pmid">30723041</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0007"><string-name><surname>Mayo</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lustberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Dhillon</surname><given-names>HM</given-names></string-name>, et al. <article-title>Cancer‐related cognitive impairment in patients with non‐central nervous system malignancies: an overview for oncology providers from the MASCC neurological complications study group</article-title>. <source>Support Care Cancer</source>. <year>2021</year>;<volume>29</volume>(<issue>6</issue>):<fpage>2821</fpage>‐<lpage>2840</lpage>.<pub-id pub-id-type="pmid">33231809</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0008"><string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Caeyenberghs</surname><given-names>K</given-names></string-name>. <article-title>Longitudinal assessment of chemotherapy‐induced changes in brain and cognitive functioning: a systematic review</article-title>. <source>Neurosci Biobehav Rev</source>. <year>2018</year>;<volume>92</volume>:<fpage>304</fpage>‐<lpage>371</lpage>.<pub-id pub-id-type="pmid">29791867</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0009"><string-name><surname>Vogelbaum</surname><given-names>MA</given-names></string-name>, <string-name><surname>Brown</surname><given-names>PD</given-names></string-name>, <string-name><surname>Messersmith</surname><given-names>H</given-names></string-name>, et al. <article-title>Treatment for brain metastases: ASCO‐SNO‐ASTRO guideline</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>5</issue>):<fpage>492</fpage>‐<lpage>516</lpage>.<pub-id pub-id-type="pmid">34932393</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0010"><string-name><surname>Brown</surname><given-names>PD</given-names></string-name>, <string-name><surname>Pugh</surname><given-names>S</given-names></string-name>, <string-name><surname>Laack</surname><given-names>NN</given-names></string-name>, et al. <article-title>Memantine for the prevention of cognitive dysfunction in patients receiving whole‐brain radiotherapy: a randomized, double‐blind, placebo‐controlled trial</article-title>. <source>Neuro Oncol</source>. <year>2013</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1429</fpage>‐<lpage>1437</lpage>.<pub-id pub-id-type="pmid">23956241</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0011"><string-name><surname>Brown</surname><given-names>PD</given-names></string-name>, <string-name><surname>Gondi</surname><given-names>V</given-names></string-name>, <string-name><surname>Pugh</surname><given-names>S</given-names></string-name>, et al. <article-title>Hippocampal avoidance during whole‐brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001</article-title>. <source>J Clin Oncol off J Am Soc Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>10</issue>):<fpage>1019</fpage>‐<lpage>1029</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0012"><string-name><surname>Cole</surname><given-names>PD</given-names></string-name>, <string-name><surname>Vijayanathan</surname><given-names>V</given-names></string-name>, <string-name><surname>Ali</surname><given-names>NF</given-names></string-name>, et al. <article-title>Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits</article-title>. <source>Clin Cancer Res</source>. <year>2013</year>;<volume>19</volume>(<issue>16</issue>):<fpage>4446</fpage>‐<lpage>4454</lpage>.<pub-id pub-id-type="pmid">23833301</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0013"><string-name><surname>Sung</surname><given-names>PS</given-names></string-name>, <string-name><surname>Chen</surname><given-names>PW</given-names></string-name>, <string-name><surname>Yen</surname><given-names>CJ</given-names></string-name>, et al. <article-title>Memantine protects against paclitaxel‐induced cognitive impairment through modulation of neurogenesis and inflammation in mice</article-title>. <source>Cancers</source>. <year>2021</year>;<volume>13</volume>(<issue>16</issue>):<fpage>4177</fpage>.<pub-id pub-id-type="pmid">34439331</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0014"><string-name><surname>Katzman</surname><given-names>R</given-names></string-name>, <string-name><surname>Brown</surname><given-names>T</given-names></string-name>, <string-name><surname>Fuld</surname><given-names>P</given-names></string-name>, <string-name><surname>Peck</surname><given-names>A</given-names></string-name>, <string-name><surname>Schechter</surname><given-names>R</given-names></string-name>, <string-name><surname>Schimmel</surname><given-names>H</given-names></string-name>. <article-title>Validation of a short orientation‐memory‐concentration test of cognitive impairment</article-title>. <source>Am J Psychiatry</source>. <year>1983</year>;<volume>140</volume>(<issue>6</issue>):<fpage>734</fpage>‐<lpage>739</lpage>.<pub-id pub-id-type="pmid">6846631</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0015"><string-name><surname>Horne</surname><given-names>R</given-names></string-name>, <string-name><surname>Weinman</surname><given-names>J</given-names></string-name>, <string-name><surname>Hankins</surname><given-names>M</given-names></string-name>. <article-title>The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication</article-title>. <source>Psychol Health</source>. <year>1999</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>‐<lpage>24</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0016"><string-name><surname>Fray</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Robbins</surname><given-names>TW</given-names></string-name>. <article-title>CANTAB battery: proposed utility in neurotoxicology</article-title>. <source>Neurotoxicol Teratol</source>. <year>1996</year>;<volume>18</volume>:<fpage>499</fpage>‐<lpage>504</lpage>.<pub-id pub-id-type="pmid">8866544</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0017"><string-name><surname>Janelsins</surname><given-names>MC</given-names></string-name>, <string-name><surname>Heckler</surname><given-names>CE</given-names></string-name>, <string-name><surname>Peppone</surname><given-names>LJ</given-names></string-name>, et al. <article-title>Longitudinal trajectory and characterization of cancer‐related cognitive impairment in a Nationwide cohort study</article-title>. <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>32</issue>):<elocation-id>JCO2018786624</elocation-id>.<pub-id pub-id-type="pmid">30240328</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0018"><string-name><surname>Chan</surname><given-names>A</given-names></string-name>, <string-name><surname>Yeo</surname><given-names>A</given-names></string-name>, <string-name><surname>Shwe</surname><given-names>M</given-names></string-name>, et al. <article-title>An evaluation of DNA methyltransferase 1 (DNMT1) single nucleotide polymorphisms and chemotherapy‐associated cognitive impairment: a prospective, longitudinal study</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>14570</fpage>.<pub-id pub-id-type="pmid">31601979</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0019"><string-name><surname>Magnuson</surname><given-names>A</given-names></string-name>, <string-name><surname>Lei</surname><given-names>L</given-names></string-name>, <string-name><surname>Gilmore</surname><given-names>N</given-names></string-name>, et al. <article-title>Longitudinal relationship between frailty and cognition in patients 50 years and older with breast cancer</article-title>. <source>J Am Geriatr Soc</source>. <year>2019</year>;<volume>67</volume>(<issue>5</issue>):<fpage>928</fpage>‐<lpage>936</lpage>.<pub-id pub-id-type="pmid">31034595</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0020"><string-name><surname>Vardy</surname><given-names>J</given-names></string-name>, <string-name><surname>Dhillon</surname><given-names>HM</given-names></string-name>, <string-name><surname>Pond</surname><given-names>GR</given-names></string-name>, et al. <article-title>Cognitive function and fatigue after diagnosis of colorectal cancer</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>(<issue>12</issue>):<fpage>2404</fpage>‐<lpage>2412</lpage>.<pub-id pub-id-type="pmid">25214544</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0021"><string-name><surname>Ahles</surname><given-names>TA</given-names></string-name>, <string-name><surname>Saykin</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>BC</given-names></string-name>, et al. <article-title>Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve</article-title>. <source>J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>4434</fpage>‐<lpage>4440</lpage>.<pub-id pub-id-type="pmid">20837957</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0022"><string-name><surname>Mandelblatt</surname><given-names>JS</given-names></string-name>, <string-name><surname>Small</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Luta</surname><given-names>G</given-names></string-name>, et al. <article-title>Cancer‐related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study</article-title>. <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>32</issue>):<elocation-id>JCO1800140</elocation-id>.<pub-id pub-id-type="pmid">30281396</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0023"><string-name><surname>Valentine</surname><given-names>TR</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>DM</given-names></string-name>, <string-name><surname>Jones</surname><given-names>JA</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>BL</given-names></string-name>. <article-title>Construct validity of PROMIS® cognitive function in cancer patients and noncancer controls</article-title>. <source>Heal Psychol</source>. <year>2019</year>;<volume>38</volume>(<issue>5</issue>):<fpage>351</fpage>‐<lpage>358</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0024"><string-name><surname>Cella</surname><given-names>D</given-names></string-name>, <string-name><surname>Choi</surname><given-names>S</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>S</given-names></string-name>, et al. <article-title>Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment</article-title>. <source>Qual Life Res</source>. <year>2014</year>;<volume>23</volume>(<issue>10</issue>):<fpage>2651</fpage>‐<lpage>2661</lpage>.<pub-id pub-id-type="pmid">24938431</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0025"><string-name><surname>Rothrock</surname><given-names>NE</given-names></string-name>, <string-name><surname>Cook</surname><given-names>KF</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>M</given-names></string-name>, <string-name><surname>Cella</surname><given-names>D</given-names></string-name>, <string-name><surname>Smith</surname><given-names>AW</given-names></string-name>, <string-name><surname>Yount</surname><given-names>SE</given-names></string-name>. <article-title>Establishing clinically‐relevant terms and severity thresholds for patient‐reported outcomes measurement information system(®) (PROMIS(®)) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setti</article-title>. <source>Qual Life Res</source>. <year>2019</year>;<volume>28</volume>(<issue>12</issue>):<fpage>3355</fpage>‐<lpage>3362</lpage>.<pub-id pub-id-type="pmid">31410640</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0026"><string-name><surname>Mar Fan</surname><given-names>HG</given-names></string-name>, <string-name><surname>Clemons</surname><given-names>M</given-names></string-name>, <string-name><surname>Xu</surname><given-names>W</given-names></string-name>, et al. <article-title>A randomised, placebo‐controlled, double‐blind trial of the effects of d‐methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer</article-title>. <source>Support Care Cancer</source>. <year>2008</year>;<volume>16</volume>(<issue>6</issue>):<fpage>577</fpage>‐<lpage>583</lpage>.<pub-id pub-id-type="pmid">17972110</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0027"><string-name><surname>Gehring</surname><given-names>K</given-names></string-name>, <string-name><surname>Patwardhan</surname><given-names>SY</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, et al. <article-title>A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor</article-title>. <source>J Neurooncol</source>. <year>2012</year>;<volume>107</volume>(<issue>1</issue>):<fpage>165</fpage>‐<lpage>174</lpage>.<pub-id pub-id-type="pmid">21964738</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0028"><string-name><surname>Butler</surname><given-names>JM</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Case</surname><given-names>LD</given-names></string-name>, <string-name><surname>Atkins</surname><given-names>J</given-names></string-name>, et al. <article-title>A phase III, double‐blind, placebo‐controlled prospective randomized clinical trial of d‐threo‐methylphenidate HCl in brain tumor patients receiving radiation therapy</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2007</year>;<volume>69</volume>(<issue>5</issue>):<fpage>1496</fpage>‐<lpage>1501</lpage>.<pub-id pub-id-type="pmid">17869448</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0029"><string-name><surname>Correa</surname><given-names>DD</given-names></string-name>, <string-name><surname>Kryza‐Lacombe</surname><given-names>M</given-names></string-name>, <string-name><surname>Baser</surname><given-names>RE</given-names></string-name>, <string-name><surname>Beal</surname><given-names>K</given-names></string-name>, <string-name><surname>DeAngelis</surname><given-names>LM</given-names></string-name>. <article-title>Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study</article-title>. <source>J Neurooncol</source>. <year>2016</year>;<volume>127</volume>(<issue>2</issue>):<fpage>313</fpage>‐<lpage>319</lpage>.<pub-id pub-id-type="pmid">26738844</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0030"><string-name><surname>Lawrence</surname><given-names>JA</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>L</given-names></string-name>, <string-name><surname>Balcueva</surname><given-names>EP</given-names></string-name>, et al. <article-title>A study of donepezil in female breast cancer survivors with self‐reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy</article-title>. <source>J Cancer Surviv</source>. <year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>176</fpage>‐<lpage>184</lpage>.<pub-id pub-id-type="pmid">26130292</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="miscellaneous" id="cam45619-cit-0031"><article-title>FDA drug safety communication: Erythropoiesis‐stimulating agents (ESAs): Procrit, Epogen and Aranesp</article-title>. [Internet] <year>2011</year>. Available from: <ext-link xlink:href="http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm" ext-link-type="uri">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm</ext-link></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0032"><string-name><surname>McShane</surname><given-names>R</given-names></string-name>, <string-name><surname>Areosa Sastre</surname><given-names>A</given-names></string-name>, <string-name><surname>Minakaran</surname><given-names>N</given-names></string-name>. <article-title>Memantine for dementia</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>;<volume>3</volume>(<issue>3</issue>):<elocation-id>CD003154</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD003154.pub5</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0033"><string-name><surname>Nyrop</surname><given-names>KA</given-names></string-name>, <string-name><surname>Deal</surname><given-names>AM</given-names></string-name>, <string-name><surname>Shachar</surname><given-names>SS</given-names></string-name>, et al. <article-title>Patient‐reported toxicities during chemotherapy regimens in current clinical practice for early breast cancer</article-title>. <source>Oncologist</source>. <year>2019</year>;<volume>24</volume>(<issue>6</issue>):<fpage>762</fpage>‐<lpage>771</lpage>.<pub-id pub-id-type="pmid">30552158</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0034"><string-name><surname>Wesnes</surname><given-names>KA</given-names></string-name>, <string-name><surname>Aarsland</surname><given-names>D</given-names></string-name>, <string-name><surname>Ballard</surname><given-names>C</given-names></string-name>, <string-name><surname>Londos</surname><given-names>E</given-names></string-name>. <article-title>Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2015</year>;<volume>30</volume>(<issue>1</issue>):<fpage>46</fpage>‐<lpage>54</lpage>.<pub-id pub-id-type="pmid">24737460</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0035"><string-name><surname>Yang</surname><given-names>JC</given-names></string-name>, <string-name><surname>Rodriguez</surname><given-names>A</given-names></string-name>, <string-name><surname>Royston</surname><given-names>A</given-names></string-name>, et al. <article-title>Memantine improves attentional processes in fragile X‐associated tremor/ataxia syndrome: electrophysiological evidence from a randomized controlled trial</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>21719</fpage>.<pub-id pub-id-type="pmid">26898832</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0036"><string-name><surname>Askari</surname><given-names>S</given-names></string-name>, <string-name><surname>Mokhtari</surname><given-names>S</given-names></string-name>, <string-name><surname>Shariat</surname><given-names>SV</given-names></string-name>, <string-name><surname>Shariati</surname><given-names>B</given-names></string-name>, <string-name><surname>Yarahmadi</surname><given-names>M</given-names></string-name>, <string-name><surname>Shalbafan</surname><given-names>M</given-names></string-name>. <article-title>Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive‐compulsive disorder: a double‐blind placebo‐controlled, randomized clinical trial</article-title>. <source>BMC Psychiatry</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>34</fpage>.<pub-id pub-id-type="pmid">35022014</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0037"><string-name><surname>Ferris</surname><given-names>S</given-names></string-name>, <string-name><surname>Schneider</surname><given-names>L</given-names></string-name>, <string-name><surname>Farmer</surname><given-names>M</given-names></string-name>, <string-name><surname>Kay</surname><given-names>G</given-names></string-name>, <string-name><surname>Crook</surname><given-names>T</given-names></string-name>. <article-title>A double‐blind, placebo‐controlled trial of memantine in age‐associated memory impairment (memantine in AAMI)</article-title>. <source>Int J Geriatr Psychiatry A J Psychiatry Late Life Allied Sci</source>. <year>2007</year>;<volume>22</volume>(<issue>5</issue>):<fpage>448</fpage>‐<lpage>455</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0038"><string-name><surname>Cerulla</surname><given-names>N</given-names></string-name>, <string-name><surname>Arcusa</surname><given-names>À</given-names></string-name>, <string-name><surname>Navarro</surname><given-names>JB</given-names></string-name>, et al. <article-title>Cognitive impairment following chemotherapy for breast cancer: the impact of practice effect on results</article-title>. <source>J Clin Exp Neuropsychol</source>. <year>2019</year>;<volume>41</volume>(<issue>3</issue>):<fpage>290</fpage>‐<lpage>299</lpage>.<pub-id pub-id-type="pmid">30477390</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0039"><string-name><surname>Collins</surname><given-names>B</given-names></string-name>, <string-name><surname>MacKenzie</surname><given-names>J</given-names></string-name>, <string-name><surname>Tasca</surname><given-names>GA</given-names></string-name>, <string-name><surname>Scherling</surname><given-names>C</given-names></string-name>, <string-name><surname>Smith</surname><given-names>A</given-names></string-name>. <article-title>Cognitive effects of chemotherapy in breast cancer patients: a dose–response study</article-title>. <source>Psychooncology</source>. <year>2013</year>;<volume>22</volume>(<issue>7</issue>):<fpage>1517</fpage>‐<lpage>1527</lpage>.<pub-id pub-id-type="pmid">22936651</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0040"><string-name><surname>Wefel</surname><given-names>JS</given-names></string-name>, <string-name><surname>Saleeba</surname><given-names>AK</given-names></string-name>, <string-name><surname>Buzdar</surname><given-names>AU</given-names></string-name>, <string-name><surname>Meyers</surname><given-names>CA</given-names></string-name>. <article-title>Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer</article-title>. <source>Cancer</source>. <year>2010</year>;<volume>116</volume>(<issue>14</issue>):<fpage>3348</fpage>‐<lpage>3356</lpage>.<pub-id pub-id-type="pmid">20564075</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0041"><string-name><surname>Jansen</surname><given-names>CE</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>B</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Miaskowski</surname><given-names>C</given-names></string-name>. <article-title>A prospective longitudinal study of chemotherapy‐induced cognitive changes in breast cancer patients</article-title>. <source>Support Care Cancer</source>. <year>2011</year>;<volume>19</volume>(<issue>10</issue>):<fpage>1647</fpage>‐<lpage>1656</lpage>.<pub-id pub-id-type="pmid">20820813</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0042"><string-name><surname>Hermelink</surname><given-names>K</given-names></string-name>, <string-name><surname>Untch</surname><given-names>M</given-names></string-name>, <string-name><surname>Lux</surname><given-names>MP</given-names></string-name>, et al. <article-title>Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study</article-title>. <source>Cancer</source>. <year>2007</year>;<volume>109</volume>(<issue>9</issue>):<fpage>1905</fpage>‐<lpage>1913</lpage>.<pub-id pub-id-type="pmid">17351951</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0043"><string-name><surname>Hurria</surname><given-names>A</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>C</given-names></string-name>, <string-name><surname>Hudis</surname><given-names>C</given-names></string-name>, et al. <article-title>Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study</article-title>. <source>J Am Geriatr Soc</source>. <year>2006</year>;<volume>54</volume>(<issue>6</issue>):<fpage>925</fpage>‐<lpage>931</lpage>.<pub-id pub-id-type="pmid">16776787</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0044"><string-name><surname>Wefel</surname><given-names>JS</given-names></string-name>, <string-name><surname>Vardy</surname><given-names>J</given-names></string-name>, <string-name><surname>Ahles</surname><given-names>T</given-names></string-name>, <string-name><surname>Schagen</surname><given-names>SB</given-names></string-name>. <article-title>International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer</article-title>. <source>Lancet Oncol</source>. <year>2011</year>;<volume>12</volume>(<issue>7</issue>):<fpage>703</fpage>‐<lpage>708</lpage>.<pub-id pub-id-type="pmid">21354373</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0045"><string-name><surname>Horowitz</surname><given-names>TS</given-names></string-name>, <string-name><surname>Suls</surname><given-names>J</given-names></string-name>, <string-name><surname>Treviño</surname><given-names>M</given-names></string-name>. <article-title>A call for a neuroscience approach to cancer‐related cognitive impairment</article-title>. <source>Trends Neurosci</source>. <year>2018</year>;<volume>41</volume>(<issue>8</issue>):<fpage>493</fpage>‐<lpage>496</lpage>.<pub-id pub-id-type="pmid">29907436</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0046"><string-name><surname>Bernstein</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Catton</surname><given-names>PA</given-names></string-name>, <string-name><surname>Tannock</surname><given-names>IF</given-names></string-name>. <article-title>Intra‐individual variability in women with breast cancer</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2014</year>;<volume>20</volume>(<issue>4</issue>):<fpage>380</fpage>‐<lpage>390</lpage>.<pub-id pub-id-type="pmid">24621519</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0047"><string-name><surname>Yao</surname><given-names>C</given-names></string-name>, <string-name><surname>Rich</surname><given-names>JB</given-names></string-name>, <string-name><surname>Tirona</surname><given-names>K</given-names></string-name>, <string-name><surname>Bernstein</surname><given-names>LJ</given-names></string-name>. <article-title>Intraindividual variability in reaction time before and after neoadjuvant chemotherapy in women diagnosed with breast cancer</article-title>. <source>Psychooncology</source>. <year>2017</year>;<volume>26</volume>(<issue>12</issue>):<fpage>2261</fpage>‐<lpage>2268</lpage>.<pub-id pub-id-type="pmid">28002893</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0048"><string-name><surname>Collins</surname><given-names>B</given-names></string-name>, <string-name><surname>Widmann</surname><given-names>G</given-names></string-name>, <string-name><surname>Tasca</surname><given-names>GA</given-names></string-name>. <article-title>Effectiveness of intraindividual variability in detecting subtle cognitive performance deficits in breast cancer patients</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2018</year>;<volume>24</volume>(<issue>7</issue>):<fpage>724</fpage>‐<lpage>734</lpage>.<pub-id pub-id-type="pmid">29880075</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0049"><string-name><surname>Gaynor</surname><given-names>AM</given-names></string-name>, <string-name><surname>Ahsan</surname><given-names>A</given-names></string-name>, <string-name><surname>Jung</surname><given-names>D</given-names></string-name>, et al. <article-title>Novel computerized neurocognitive test battery is sensitive to cancer‐related cognitive deficits in survivors</article-title>. <source>J Cancer Surviv</source>. <year>2022</year>. doi:<pub-id pub-id-type="doi">10.1007/s11764-022-01232-w</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0050"><string-name><surname>Duff</surname><given-names>K</given-names></string-name>. <article-title>Evidence‐based indicators of neuropsychological change in the individual patient: relevant concepts and methods</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2012</year>;<volume>27</volume>(<issue>3</issue>):<fpage>248</fpage>‐<lpage>261</lpage>.<pub-id pub-id-type="pmid">22382384</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0051"><string-name><surname>Andreotti</surname><given-names>C</given-names></string-name>, <string-name><surname>Root</surname><given-names>JC</given-names></string-name>, <string-name><surname>Schagen</surname><given-names>SB</given-names></string-name>, et al. <article-title>Reliable change in neuropsychological assessment of breast cancer survivors</article-title>. <source>Psychooncology</source>. <year>2015</year>;<volume>25</volume>(<issue>1</issue>):<fpage>43</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">25808921</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0052"><string-name><surname>Dmitrienko</surname><given-names>A</given-names></string-name>, <string-name><surname>Offen</surname><given-names>WW</given-names></string-name>, <string-name><surname>Westfall</surname><given-names>PH</given-names></string-name>. <article-title>Gatekeeping strategies for clinical trials that do not require all primary effects to be significant</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>(<issue>15</issue>):<fpage>2387</fpage>‐<lpage>2400</lpage>.<pub-id pub-id-type="pmid">12872297</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0053"><string-name><surname>Dmitrienko</surname><given-names>A</given-names></string-name>, <string-name><surname>Tamhane</surname><given-names>AC</given-names></string-name>. <article-title>Gatekeeping procedures with clinical trial applications</article-title>. <source>Pharm Stat</source>. <year>2007</year>;<volume>6</volume>(<issue>3</issue>):<fpage>171</fpage>‐<lpage>180</lpage>.<pub-id pub-id-type="pmid">17583553</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0054"><string-name><surname>Koch</surname><given-names>GG</given-names></string-name>, <string-name><surname>Gansky</surname><given-names>SA</given-names></string-name>. <article-title>Statistical considerations for multiplicity in confirmatory protocols</article-title>. <source>Drug Inf J</source>. <year>1996</year>;<volume>30</volume>(<issue>2</issue>):<fpage>523</fpage>‐<lpage>534</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0055"><string-name><surname>Ahles</surname><given-names>TA</given-names></string-name>, <string-name><surname>Saykin</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Noll</surname><given-names>WW</given-names></string-name>, et al. <article-title>The relationship of APOE genotype to neuropsychological performance in long‐term cancer survivors treated with standard dose chemotherapy</article-title>. <source>Psychooncology</source>. <year>2003</year>;<volume>12</volume>:<fpage>612</fpage>‐<lpage>619</lpage>.<pub-id pub-id-type="pmid">12923801</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0056"><string-name><surname>Ahles</surname><given-names>TA</given-names></string-name>, <string-name><surname>Saykin</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>BC</given-names></string-name>, et al. <article-title>Cognitive function in breast cancer patients prior to adjuvant treatment</article-title>. <source>Breast Cancer Res Treat</source>. <year>2008</year>;<volume>110</volume>(<issue>1</issue>):<fpage>143</fpage>‐<lpage>152</lpage>.<pub-id pub-id-type="pmid">17674194</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0057"><string-name><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Smith</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>W</given-names></string-name>, et al. <article-title>Effect of exercise, escitalopram, or placebo on anxiety in patients with coronary heart disease: the understanding the benefits of exercise and escitalopram in anxious patients with coronary heart disease (UNWIND) randomized clinical trial</article-title>. <source>JAMA Psychiat</source>. <year>2021</year>;<volume>78</volume>(<issue>11</issue>):<fpage>1270</fpage>‐<lpage>1278</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0058"><string-name><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hinderliter</surname><given-names>AL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>PJ</given-names></string-name>, et al. <article-title>Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial</article-title>. <source>Circulation</source>. <year>2021</year>;<volume>144</volume>(<issue>15</issue>):<fpage>1212</fpage>‐<lpage>1226</lpage>.<pub-id pub-id-type="pmid">34565172</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0059"><string-name><surname>Janelsins</surname><given-names>MC</given-names></string-name>, <string-name><surname>Heckler</surname><given-names>CE</given-names></string-name>, <string-name><surname>Peppone</surname><given-names>LJ</given-names></string-name>, et al. <article-title>Cognitive complaints in survivors of breast cancer after chemotherapy compared with age‐matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study</article-title>. <source>J Clin Oncol</source>. <year>2017</year>;<volume>35</volume>(<issue>5</issue>):<fpage>506</fpage>‐<lpage>514</lpage>.<pub-id pub-id-type="pmid">28029304</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="book" id="cam45619-cit-0060"><collab collab-type="authors">American Cancer Society</collab>
. <source>Breast Cancer Facts &amp; Figures 2019–2020</source>. <publisher-name>American Cancer Society, Inc</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0061"><string-name><surname>Munro Cullum</surname><given-names>C</given-names></string-name>, <string-name><surname>Hynan</surname><given-names>LS</given-names></string-name>, <string-name><surname>Grosch</surname><given-names>M</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>M</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>MF</given-names></string-name>. <article-title>Teleneuropsychology: evidence for video teleconference‐based neuropsychological assessment</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2014</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1028</fpage>‐<lpage>1033</lpage>.<pub-id pub-id-type="pmid">25343269</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0062"><string-name><surname>Wadsworth</surname><given-names>HE</given-names></string-name>, <string-name><surname>Dhima</surname><given-names>K</given-names></string-name>, <string-name><surname>Womack</surname><given-names>KB</given-names></string-name>, et al. <article-title>Validity of Teleneuropsychological assessment in older patients with cognitive disorders</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2018</year>;<volume>33</volume>(<issue>8</issue>):<fpage>1040</fpage>‐<lpage>1045</lpage>.<pub-id pub-id-type="pmid">29329363</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0063"><string-name><surname>Bilder</surname><given-names>RM</given-names></string-name>, <string-name><surname>Postal</surname><given-names>KS</given-names></string-name>, <string-name><surname>Barisa</surname><given-names>M</given-names></string-name>, et al. <article-title>Inter organizational practice committee recommendations/guidance for teleneuropsychology in response to the COVID‐19 pandemic</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2020</year>;<volume>35</volume>(<issue>6</issue>):<fpage>647</fpage>‐<lpage>659</lpage>.<pub-id pub-id-type="pmid">32666093</pub-id></mixed-citation>
              </ref>
              <ref id="cam45619-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0064"><string-name><surname>Kohli</surname><given-names>M</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>A</given-names></string-name>, <string-name><surname>Sun‐Suslow</surname><given-names>N</given-names></string-name>, et al. <article-title>Concurrent validity and reliability of at‐home teleneuropsychological evaluations among people with and without HIV</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2022</year>;<volume>1–12</volume>:<fpage>1</fpage>‐<lpage>12</lpage>.</mixed-citation>
              </ref>
              <ref id="cam45619-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="cam45619-cit-0065"><string-name><surname>Gardner</surname><given-names>MM</given-names></string-name>, <string-name><surname>Aslanzadeh</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Zarrella</surname><given-names>GV</given-names></string-name>, <string-name><surname>Braun</surname><given-names>SE</given-names></string-name>, <string-name><surname>Loughan</surname><given-names>AR</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>MW</given-names></string-name>. <article-title>Cancer, cognition, and COVID: delivering direct‐to‐home teleneuropsychology services to neuro‐oncology patients</article-title>. <source>Neuro‐Oncol Pract</source>. <year>2021</year>;<volume>8</volume>(<issue>4</issue>):<fpage>485</fpage>‐<lpage>496</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
